Short answer
NEOGEN CORP (NEOG) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal 2026 third-quarter results covered period ended February 28, 2026.
NEOGEN CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal 2026 third-quarter results covered period ended February 28, 2026
- Results announced April 9, 2026 through press release attached as Exhibit 99.1
- Investors should review Exhibit 99.1 for financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 FY26 revenue $211.2M, down 4.4%; Food Safety grew 2.6%, while Animal Safety fell 20.1% on supplier disruptions
- GAAP net loss $17.0M, or $(0.08) EPS; adjusted net income $19.4M, or $0.09 EPS
- Adjusted EBITDA $48.2M with 22.8% margin, up 80 basis points year over year and 110 basis points sequentially
- FY26 revenue guidance raised to $857M-$860M; adjusted EBITDA guidance maintained at approximately $175M
- Genomics sale to Zoetis for $160.0M expected to generate approximately $140.0M net proceeds, supporting leverage below three times by end-2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NEOGEN CORP 8-K filings
Get the next NEOG 8-K as it lands
Follow NEOG for push alerts, or ask the research agent what this filing means.